12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

MK-5172 regulatory update

FDA granted breakthrough therapy designation for an all-oral combination of Merck's MK-5172 and MK-8742 to treat chronic HCV infection. The...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >